For nearly two decades, we’ve assisted pharmaceutical, biotechnology, consumer health, diagnostic, digital health, and medical device organisations in attracting and developing senior executives.
Whether you are a start-up, an established corporation, or a CMO, and working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.
New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
